INCYTE CORP (INCY)
Health Care / Biotechnology
S&P 500$99.83
Below average on several measures. Research carefully.
Consider Buy
Score based on 5 of 5 models — high confidence
Is INCYTE CORP a Good Investment in 2026?
INCYTE CORP (INCY) scores 5.2 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates INCYTE CORP as Strong (7/9). The Graham model is the least favorable, rating it Neutral. INCYTE CORP ranks #495 out of 1126 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Valuation
Trades at 16x earnings — near sector median of 26x.
Fair value estimate not available for this stock.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Strong
7/9
Buffett
Strong
Business quality & competitive moat
Graham
Neutral
60% above fair value
Lynch
Strong
PEG 0.8 · Fast Grower
Greenblatt
Strong
Top half (rank 28%)
Frequently Asked Questions
Is INCYTE CORP (INCY) a good investment?
What is INCYTE CORP's Piotroski F-Score?
Is INCY overvalued or undervalued?
How does INCY compare to other Health Care stocks?
What do investment models say about INCY?
Similar Stocks
Compare INCY with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer